CN1136853C - 含β-内酰胺抗生素的片剂及其制备方法 - Google Patents

含β-内酰胺抗生素的片剂及其制备方法 Download PDF

Info

Publication number
CN1136853C
CN1136853C CNB971926492A CN97192649A CN1136853C CN 1136853 C CN1136853 C CN 1136853C CN B971926492 A CNB971926492 A CN B971926492A CN 97192649 A CN97192649 A CN 97192649A CN 1136853 C CN1136853 C CN 1136853C
Authority
CN
China
Prior art keywords
tablet
weight
synthetic sweetener
lactam antibiotic
tablets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB971926492A
Other languages
English (en)
Chinese (zh)
Other versions
CN1212626A (zh
Inventor
ɽ�ھü�
山口久己
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of CN1212626A publication Critical patent/CN1212626A/zh
Application granted granted Critical
Publication of CN1136853C publication Critical patent/CN1136853C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Seasonings (AREA)
CNB971926492A 1996-02-29 1997-02-21 含β-内酰胺抗生素的片剂及其制备方法 Expired - Fee Related CN1136853C (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP4274396 1996-02-29
JP42743/1996 1996-02-29
JP42743/96 1996-02-29
JP320264/96 1996-11-29
JP32026496 1996-11-29
JP320264/1996 1996-11-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN02141260A Division CN1409995A (zh) 1996-02-29 2002-06-26 合成甜味剂

Publications (2)

Publication Number Publication Date
CN1212626A CN1212626A (zh) 1999-03-31
CN1136853C true CN1136853C (zh) 2004-02-04

Family

ID=26382481

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB971926492A Expired - Fee Related CN1136853C (zh) 1996-02-29 1997-02-21 含β-内酰胺抗生素的片剂及其制备方法
CN02141260A Pending CN1409995A (zh) 1996-02-29 2002-06-26 合成甜味剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN02141260A Pending CN1409995A (zh) 1996-02-29 2002-06-26 合成甜味剂

Country Status (23)

Country Link
US (4) US6423341B1 (enExample)
EP (2) EP0890359B1 (enExample)
JP (1) JP3180350B2 (enExample)
KR (1) KR20040058360A (enExample)
CN (2) CN1136853C (enExample)
AR (1) AR006012A1 (enExample)
AT (2) ATE287218T1 (enExample)
AU (1) AU724946B2 (enExample)
BR (1) BR9707780A (enExample)
CA (1) CA2248179C (enExample)
DE (2) DE69712332T2 (enExample)
DK (2) DK0890359T3 (enExample)
EA (1) EA001089B1 (enExample)
ES (2) ES2173420T3 (enExample)
HU (1) HU227821B1 (enExample)
IL (1) IL125214A0 (enExample)
MX (1) MX9806265A (enExample)
NZ (2) NZ330864A (enExample)
PT (2) PT890359E (enExample)
TR (1) TR199801680T2 (enExample)
TW (1) TW473393B (enExample)
WO (1) WO1997031639A1 (enExample)
ZA (1) ZA971584B (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6746105B2 (en) 1997-07-15 2004-06-08 Silverbrook Research Pty. Ltd. Thermally actuated ink jet printing mechanism having a series of thermal actuator units
US5948440A (en) * 1997-12-17 1999-09-07 Ranbaxy Laboratories Limited Modified release matrix formulation of cefaclor and cephalexin
EP1736144B1 (en) 1998-05-18 2015-11-11 Takeda Pharmaceutical Company Limited Orally disintegrable tablets
MY154010A (en) * 1998-07-28 2015-04-30 Takeda Pharmaceutical Rapidly disintegrable solid preparation
US20070160675A1 (en) * 1998-11-02 2007-07-12 Elan Corporation, Plc Nanoparticulate and controlled release compositions comprising a cephalosporin
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
BRPI0014470B1 (pt) * 1999-10-08 2016-08-23 Affinium Pharm Inc compostos inibidores de fab i, composição farmacêutica, processo de preparação dos compostos e uso dos compostos para a produção de medicamento para tratamento de infecções bacterianas
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
FR2814679B1 (fr) * 2000-09-29 2003-04-11 Cll Pharma Compositions pharmaceutiques dispersibles a base de cephalosporines, leur procede de preparation et leur utilisation
CA2444597A1 (en) * 2001-04-06 2002-10-06 Affinium Pharmaceuticals, Inc. Fab i inhibitors
GB0123400D0 (en) * 2001-09-28 2001-11-21 Novartis Ag Organic compounds
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
JP4526247B2 (ja) * 2002-07-08 2010-08-18 第一三共株式会社 経口用セファロスポリン製剤
TW200404550A (en) * 2002-07-08 2004-04-01 Sankyo Co Cepharospolin formulation for oral use
JP2006500356A (ja) * 2002-08-13 2006-01-05 サンド・アクチエンゲゼルシヤフト セフジニル中間体
JP4859460B2 (ja) * 2002-12-06 2012-01-25 アフィニウム ファーマシューティカルズ， インク． ヘテロ環化合物、その製造方法および治療におけるその使用
EP1608377B1 (en) * 2003-03-17 2008-10-01 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
JPWO2004085443A1 (ja) * 2003-03-24 2006-06-29 ア・チ・エツセ・ドブフアル・エツセ・ピー・アー ７−［２−（２−アミノチアゾール−４−イル）−２−ヒドロキシイミノアセトアミド−３−ビニル−３−セフェム−４−カルボン酸（シン異性体）の新規結晶およびその製造方法
JP4505859B2 (ja) 2003-08-08 2010-07-21 味の素株式会社 ナテグリニド含有製剤
US20050059818A1 (en) * 2003-09-12 2005-03-17 Duerst Richard W. Polymorph of a pharmaceutical
US20050059819A1 (en) * 2003-09-12 2005-03-17 Duerst Richard W. Cefdinir pyridine salt
US20050113355A1 (en) * 2003-09-12 2005-05-26 Duerst Richard W. Cefdinir pyridine salt
JP2005162696A (ja) * 2003-12-04 2005-06-23 Nichiko Pharmaceutical Co Ltd 溶出性に優れたセフジトレンピボキシル製剤
US20080139528A1 (en) * 2003-12-10 2008-06-12 Pujara Chetan P Cefdinir oral suspension
US20050131079A1 (en) * 2003-12-10 2005-06-16 Pujara Chetan P. Cefdinir oral suspension
US20060142261A1 (en) * 2004-03-16 2006-06-29 Devalina Law Crystalline anhydrous cefdinir and crystalline cefdinir hydrates
US20060211676A1 (en) * 2004-03-16 2006-09-21 Devalina Law Crystalline anhydrous cefdinir and crystalline cefdinir hydrates
US20060142563A1 (en) * 2004-03-16 2006-06-29 Devalina Law Crystalline anhydrous cefdinir and crystalline cefdinir hydrates
US20060069079A1 (en) * 2004-09-27 2006-03-30 Sever Nancy E Stable amorphous cefdinir
BRPI0418769A (pt) * 2004-05-10 2007-10-09 Lupin Ltd composição farmacêutica compreendendo cefixima, processo para a preparação de uma forma de dosagem oral sólida compreendendo de partìculas de cefixima, método para conseguir bio-equivalência entre a forma de dosagem oral e uma suspensão e comprimido mastigável compreendendo cefixima
WO2005115347A1 (en) * 2004-05-31 2005-12-08 Sam-A Pharmaceuticals Co., Ltd. Dispersible tablet comprising beta lactam antibiotics and process for preparing the same
CA2568914C (en) * 2004-06-04 2013-09-24 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
US20060099253A1 (en) * 2004-10-20 2006-05-11 Wyeth Antibiotic product formulation
IL169678A (en) 2005-07-14 2010-11-30 Innova Sa Sweetener compositions
US20090156578A1 (en) * 2005-12-05 2009-06-18 PAULS Henry 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents
US20070128268A1 (en) * 2005-12-07 2007-06-07 Herwig Jennewein Pharmaceutical compositions comprising an antibiotic
US20090197855A1 (en) * 2006-05-01 2009-08-06 Makarand Krishnakumar Avachat Pharmaceutical compositions of cefdinir
CA2658506C (en) 2006-07-20 2016-01-26 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as fab 1 inhibitors
EP2100609A4 (en) * 2006-12-07 2010-01-06 Daiichi Sankyo Co Ltd MANNITOL- OR LACTOSE-FIXED MEDICAL PREPARATION
TWI482641B (zh) * 2006-12-07 2015-05-01 Daiichi Sankyo Co Ltd 含有低取代度羥丙基纖維素之醫藥組成物
CA2672157C (en) * 2006-12-07 2016-07-26 Daiichi Sankyo Company, Limited Method for producing solid preparation
EP2125802A4 (en) * 2007-02-16 2014-08-20 Debiopharm Int Sa SALTS, PRODRUGS AND POLYMORPHES OF FAB I INHIBITORS
TR200909785A1 (tr) * 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.
US8614315B2 (en) 2009-12-25 2013-12-24 Mahmut Bilgic Cefdinir and cefixime formulations and uses thereof
WO2011078830A1 (en) * 2009-12-25 2011-06-30 Bilgic Mahmut Rapidly dispersing effervescent formulation
TR200909786A1 (tr) * 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Sefiksim içeren efervesan tablet ve granül formülasyonu.
TR201000687A1 (tr) * 2010-01-29 2011-08-22 Bi̇lgi̇ç Mahmut Aktif madde olarak sefiksim ve klavulanik asit içeren efervesan formülasyonlar
TR201000686A1 (tr) * 2010-01-29 2011-08-22 B�Lg�� Mahmut Bakteriyel enfeksiyonların tedavisinde suda çözünebilir sefdinir ve klavulanik asit formülasyonları.@
TR201001417A1 (tr) * 2010-02-25 2011-09-21 Sanovel İlaç San. Ve Ti̇c. A. Ş. Geliştirilmiş çözünme hızına sahip sefdinir formülasyonu
WO2011139252A2 (en) * 2010-05-04 2011-11-10 Mahmut Bilgic Efervescent formulations comprising cefdinir
EP2568959A2 (en) * 2010-05-14 2013-03-20 Mahmut Bilgic Formulations comprising a third generation cephalosporin and clavulanic acid
EA021874B1 (ru) * 2010-09-13 2015-09-30 ЛИМОНОВ, Виктор Львович Фармацевтическая композиция антимикробного действия для парентерального введения и способ ее получения
TR201009166A2 (tr) * 2010-11-05 2012-05-21 Bi̇lgi̇ç Mahmut Sefdinir içeren farmasötik bileşim için üretim yöntemi
TR201010212A2 (tr) * 2010-12-08 2012-06-21 Bi̇lgi̇ç Mahmut Sefdinir içeren katı oral dozaj formu.
SI2861608T1 (sl) 2012-06-19 2019-08-30 Debiopharm International Sa Derivati predzdravila (E)-N-metil-N-((3-metilbenzofuran-2-IL)metil)- 3-(7-okso-5,6,7,8-tetrahidro-1 ,8-nafthiridin-3-il)akrilamid
WO2014051532A1 (en) * 2012-09-28 2014-04-03 Bilgic Mahmut Pharmaceutical tablet formulations comprising cefdinir
PT2903457T (pt) * 2012-10-02 2018-03-06 Montero Gida Sanayi Ve Ticaret As Formulação de mogrosídeo e um seu processo de produção
WO2014057059A1 (en) 2012-10-11 2014-04-17 Sanovel Ilac Sanayi Ve Ticaret A.S. Effervescent cefdinir formulation
EP2815743A1 (en) 2013-06-21 2014-12-24 Sanovel Ilac Sanayi ve Ticaret A.S. Ceftibuten formulations
US10231476B2 (en) 2014-04-04 2019-03-19 Douxmatok Ltd Sweetener compositions and foods, beverages, and consumable products made thereof
US10207004B2 (en) 2014-04-04 2019-02-19 Douxmatok Ltd Method for producing sweetener compositions and sweetener compositions
US20160242439A1 (en) 2014-04-04 2016-08-25 Douxmatok Ltd Method for producing sweetener compositions and sweetener compositions
TN2018000293A1 (en) 2016-02-26 2020-01-16 Debiopharm Int Sa Medicament for treatment of diabetic foot infections
MY203711A (en) 2019-02-14 2024-07-15 Debiopharm Int Sa Afabicin formulation, method for making the same and uses thereof
WO2020249731A1 (en) 2019-06-14 2020-12-17 Debiopharm International S.A. Afabicin for use for treating bacterial infections involving biofilm
CN115607514B (zh) * 2021-07-16 2023-12-12 广州白云山天心制药股份有限公司 一种含有头孢地尼颗粒的制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3098749A (en) * 1960-11-16 1963-07-23 Abbott Lab Sweetening agent and process of producing the same
US3336199A (en) * 1963-07-03 1967-08-15 Warner Lambert Pharmaceutical Tablet composition
DE2251250C3 (de) * 1972-10-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Verfahren zur Herstellung hochdosierter Antibiotica-Tabletten
US4039673A (en) * 1973-10-30 1977-08-02 Bayer Aktiengesellschaft Penicillins and cephalosporins and their production
JPS5438167B2 (enExample) * 1974-04-27 1979-11-19
US4248894A (en) * 1979-01-17 1981-02-03 Life Savers, Inc. Long-lasting flavored chewing gum containing non-sugar sweetener codried on chalk or other filler and method
US4384005A (en) * 1980-09-26 1983-05-17 General Foods Corporation Non-friable, readily-soluble, compressed tablets and process for preparing same
JPS57150361A (en) * 1981-03-10 1982-09-17 Ajinomoto Co Inc Granule of dipeptide sweetener
US4352821A (en) * 1981-07-21 1982-10-05 Shaklee Corporation Sweet tableting agent
EP0080862B1 (en) * 1981-12-02 1985-09-25 Beecham Group Plc Pharmaceutical formulation comprising beta-lactam antibiotics
JPS58198268A (ja) * 1982-05-14 1983-11-18 Ajinomoto Co Inc 甘味料顆粒又はキユ−ブの製造法
US4600579A (en) * 1983-06-07 1986-07-15 Mallinckrodt, Inc. N-acetyl-p-aminophenol compositions containing partially gelatinized starch and method for preparing same
US4752485A (en) * 1984-10-05 1988-06-21 Warner-Lambert Company Novel sweetener delivery systems
US4722845A (en) * 1986-12-23 1988-02-02 Warner-Lambert Company Stable cinnamon-flavored chewing gum composition
EP0281200B1 (en) * 1987-03-02 1994-01-19 Yamanouchi Europe B.V. Pharmaceutical composition, pharmaceutical granulate and process for their preparation
US4915948A (en) * 1987-08-31 1990-04-10 Warner-Lambert Company Tablets having improved bioadhesion to mucous membranes
JPH01206969A (ja) * 1987-10-30 1989-08-21 Takeda Chem Ind Ltd 甘味料顆粒の製造法
JPH01149728A (ja) * 1987-12-04 1989-06-12 Fujisawa Pharmaceut Co Ltd 抗潰瘍剤
FR2634355B1 (fr) * 1988-07-25 1990-09-14 Beghin Say Sa Nouveau produit edulcorant alimentaire a base de saccharose et d'edulcorant intense et son procede de preparation
US5085876A (en) * 1988-11-16 1992-02-04 The Nutrasweet Company Fast dissolving sweetening agent including caramel
US5114929A (en) * 1989-03-21 1992-05-19 Beecham Group P.L.C. Pharmaceutical formulation
FR2669221B1 (fr) * 1990-11-15 1993-01-15 Rhone Poulenc Sante Procede de preparation par compression directe de comprimes de derives de l'acide cephalosporanique.
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
ATE216577T1 (de) * 1992-01-29 2002-05-15 Takeda Chemical Industries Ltd Schnellösliche tablette und ihre herstellung
ES2059260B1 (es) * 1992-10-06 1995-04-16 Espanola Prod Quimicos Procedimiento de preparacion de comprimidos conteniendo diclofenaco; dispersables en agua.
JP3063438B2 (ja) * 1992-12-24 2000-07-12 田辺製薬株式会社 ドパミン誘導体含有経口投与用製剤
CA2168265C (en) * 1993-07-28 1999-02-23 Kiyoshi Kimura Antidepressant
JP2994956B2 (ja) * 1994-05-31 1999-12-27 信越化学工業株式会社 低置換度ヒドロキシプロピルセルロース、その組成物およびその錠剤
DE4418957A1 (de) * 1994-05-31 1995-12-07 Merck Patent Gmbh Cefixim-Zubereitung
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
FR2722984B1 (fr) * 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.

Also Published As

Publication number Publication date
ATE216887T1 (de) 2002-05-15
ES2173420T3 (es) 2002-10-16
EP0890359A4 (enExample) 1999-01-13
AU1734797A (en) 1997-09-16
DE69732312T2 (de) 2006-04-06
DE69712332D1 (de) 2002-06-06
DE69712332T2 (de) 2002-10-02
NZ512609A (en) 2003-03-28
DK0890359T3 (da) 2002-07-01
US6423341B1 (en) 2002-07-23
HUP9901877A3 (en) 2000-04-28
US20020051816A1 (en) 2002-05-02
AR006012A1 (es) 1999-07-21
PT1166651E (pt) 2005-04-29
AU724946B2 (en) 2000-10-05
DE69732312D1 (de) 2005-02-24
DK1166651T3 (da) 2005-05-30
IL125214A0 (en) 1999-03-12
CA2248179C (en) 2007-09-18
DE69732312T8 (de) 2006-07-27
EA199800775A1 (ru) 1999-02-25
TR199801680T2 (xx) 1999-02-22
EA001089B1 (ru) 2000-10-30
JP3180350B2 (ja) 2001-06-25
EP1166651B1 (en) 2005-01-19
CN1212626A (zh) 1999-03-31
EP0890359A1 (en) 1999-01-13
HUP9901877A1 (hu) 1999-12-28
ES2231369T3 (es) 2005-05-16
HU227821B1 (en) 2012-03-28
WO1997031639A1 (en) 1997-09-04
US20070134325A1 (en) 2007-06-14
EP0890359B1 (en) 2002-05-02
KR20040058360A (ko) 2004-07-03
ATE287218T1 (de) 2005-02-15
NZ330864A (en) 2001-07-27
US20030129227A1 (en) 2003-07-10
US20020192281A1 (en) 2002-12-19
PT890359E (pt) 2003-03-31
EP1166651A1 (en) 2002-01-02
BR9707780A (pt) 1999-07-27
ZA971584B (en) 1997-09-10
TW473393B (en) 2002-01-21
CN1409995A (zh) 2003-04-16
MX9806265A (es) 1998-12-31
HK1015684A1 (en) 1999-10-22
CA2248179A1 (en) 1997-09-04

Similar Documents

Publication Publication Date Title
CN1136853C (zh) 含β-内酰胺抗生素的片剂及其制备方法
CN1251990A (zh) 含有阿莫西林和克拉维酸盐的药物制剂
CN1240374C (zh) 快速崩解的甲基纤维素片剂
CN1265882A (zh) 制备药物颗粒的方法
US5211958A (en) Pharmaceutical composition and process for its preparation
CN1787811A (zh) 口腔崩解片
JPWO1997031639A1 (ja) β−ラクタム系抗生物質含有錠剤およびその製造法
CN1494418A (zh) 口腔内快速崩解片剂
CN88101104A (zh) 药物片剂、药物粒剂及其制备方法
CN1309570A (zh) 赋形剂
CN1198615C (zh) 可再现释放活性组分加替沙星或其可药用盐或水合物的口服药物剂型
CN1863517A (zh) 快速崩解制剂
CN1747723A (zh) 含活性成分混合物的组合物及其制备方法
CN1253497A (zh) 含扑热息痛的吞咽片剂
CN1330546A (zh) 含有头孢呋肟酯的组合物
CN1095665C (zh) 改性释放2－甲基－5－硝基－1－咪唑基－乙醇组合物及其制备和使用方法
EP2902015B1 (en) Preparation method of agomelatine solid preparation
CN1147295C (zh) 包含托芬那酸或其医药可接受盐的快速释出片剂及其制法
CN1109745A (zh) 含布洛芬的固体组合物
CN1268340C (zh) 含稠合吲哚化合物的药物组合物
CN1767818A (zh) 含β－内酰胺抗生素的分散片剂及其制备方法
CN1903182A (zh) 小型化盐酸沙格雷酯经口给药制剂
EP0319074A1 (en) Pharmaceutical composition and process for its preparation
CN1943561A (zh) 普卢利沙星口腔崩解片及其制备方法
CN1612727A (zh) 含有s－腺苷甲硫氨酸的稳定颗粒及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: ASTELLAS PHARMA INC.

Free format text: FORMER NAME OR ADDRESS: FUJISAWA PHARMACEUTICAL CO., LTD.

CP03 Change of name, title or address

Address after: Tokyo, Japan

Patentee after: Yamanouchi Pharma Co., Ltd.

Address before: Osaka City, Osaka of Japan

Patentee before: Fujisawa Pharmaceutical Co., Ltd.

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040204

Termination date: 20110221